These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 36692919)

  • 21. Computational drug repositioning for rare diseases in the era of precision medicine.
    Delavan B; Roberts R; Huang R; Bao W; Tong W; Liu Z
    Drug Discov Today; 2018 Feb; 23(2):382-394. PubMed ID: 29055182
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An evaluation framework for funding drugs for rare diseases.
    Winquist E; Bell CM; Clarke JT; Evans G; Martin J; Sabharwal M; Gadhok A; Stevenson H; Coyle D
    Value Health; 2012; 15(6):982-6. PubMed ID: 22999151
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A National Approach to Reimbursement Decision-Making on Drugs for Rare Diseases in Canada? Insights from Across the Ponds.
    Short H; Stafinski T; Menon D
    Healthc Policy; 2015 May; 10(4):24-46. PubMed ID: 26142357
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Toward the development of a vibrant, super-aged society: The future of medicine and society in Japan.
    Iijima K; Arai H; Akishita M; Endo T; Ogasawara K; Kashihara N; Hayashi YK; Yumura W; Yokode M; Ouchi Y
    Geriatr Gerontol Int; 2021 Aug; 21(8):601-613. PubMed ID: 34212470
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [High cost drugs for rare diseases in Brazil: the case of lysosomal storage disorders].
    de Souza MV; Krug BC; Picon PD; Schwartz IV
    Cien Saude Colet; 2010 Nov; 15 Suppl 3():3443-54. PubMed ID: 21120332
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expensive Drugs for Rare Diseases: "Canada, We Have a Problem Here".
    Lexchin J
    Healthc Pap; 2023 Jan; 21(1):4-8. PubMed ID: 36692911
    [TBL] [Abstract][Full Text] [Related]  

  • 27. How do national guidelines frame clinical ethics practice? A comparative analysis of guidelines from the US, the UK, Canada and France.
    Gaucher N; Lantos J; Payot A
    Soc Sci Med; 2013 May; 85():74-8. PubMed ID: 23540369
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alignment of health technology assessments and price negotiations for new drugs for rare disorders in Canada: Does it lead to improved patient access?
    Rawson NSB
    J Popul Ther Clin Pharmacol; 2020 Feb; 27(1):e48-e64. PubMed ID: 32124580
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A checklist for clinical trials in rare disease: obstacles and anticipatory actions-lessons learned from the FOR-DMD trial.
    Crow RA; Hart KA; McDermott MP; Tawil R; Martens WB; Herr BE; McColl E; Wilkinson J; Kirschner J; King WM; Eagle M; Brown MW; Hirtz D; Lochmuller H; Straub V; Ciafaloni E; Shieh PB; Spinty S; Childs AM; Manzur AY; Morandi L; Butterfield RJ; Horrocks I; Roper H; Flanigan KM; Kuntz NL; Mah JK; Morrison L; Darras BT; von der Hagen M; Schara U; Wilichowski E; Mongini T; McDonald CM; Vita G; Barohn RJ; Finkel RS; Wicklund M; McMillan HJ; Hughes I; Pegoraro E; Bryan Burnette W; Howard JF; Thangarajh M; Campbell C; Griggs RC; Bushby K; Guglieri M
    Trials; 2018 May; 19(1):291. PubMed ID: 29793540
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Across space and time: social responses to large-scale biophysical systems.
    MacMynowski DP
    Environ Manage; 2007 Jun; 39(6):831-42. PubMed ID: 17415612
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incorporation of drugs for rare diseases in Brazil: is it possible to have full access to these patients?
    Biglia LV; Mendes SJ; Lima TM; Aguiar PM
    Cien Saude Colet; 2021 Nov; 26(11):5547-5560. PubMed ID: 34852089
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expensive Drugs for Rare Diseases in Canada: Time for Action Everywhere and by Everyone.
    Sirrs S; Anderson H; Jiwani B; Lun E; Nakagawa B; Regier D; Rizzardo S; McFarlane A
    Healthc Pap; 2023 Jan; 21(1):74-80. PubMed ID: 36692920
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Experience and Effectiveness of Nurse Practitioners in Orthopaedic Settings: A Comprehensive Systematic Review.
    Taylor A; Staruchowicz L
    JBI Libr Syst Rev; 2012; 10(42 Suppl):1-22. PubMed ID: 27820153
    [TBL] [Abstract][Full Text] [Related]  

  • 34. State of rare disease management in Southeast Asia.
    Shafie AA; Chaiyakunapruk N; Supian A; Lim J; Zafra M; Hassali MA
    Orphanet J Rare Dis; 2016 Aug; 11(1):107. PubMed ID: 27484654
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Public Health Approach to Palliative Care in the Canadian Context.
    Sirianni G
    Am J Hosp Palliat Care; 2020 Jul; 37(7):492-496. PubMed ID: 31795725
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Impact of Inflammatory Bowel Disease in Canada 2018: Children and Adolescents with IBD.
    Carroll MW; Kuenzig ME; Mack DR; Otley AR; Griffiths AM; Kaplan GG; Bernstein CN; Bitton A; Murthy SK; Nguyen GC; Lee K; Cooke-Lauder J; Benchimol EI
    J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S49-S67. PubMed ID: 31294385
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Estimating the budget impact of orphan medicines in Europe: 2010 - 2020.
    Schey C; Milanova T; Hutchings A
    Orphanet J Rare Dis; 2011 Sep; 6():62. PubMed ID: 21951518
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Access to new drugs for dialysis patients: challenges for indigenous and non-indigenous populations.
    Mendelssohn DC
    Clin Nephrol; 2010 Nov; 74 Suppl 1():S138-41. PubMed ID: 20979980
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Health technology assessment and price negotiation alignment for rare disorder drugs in Canada: Who benefits?
    Rawson NSB
    Orphanet J Rare Dis; 2022 Jun; 17(1):218. PubMed ID: 35698235
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oceans and Human Health (OHH): a European perspective from the Marine Board of the European Science Foundation (Marine Board-ESF).
    Moore MN; Depledge MH; Fleming L; Hess P; Lees D; Leonard P; Madsen L; Owen R; Pirlet H; Seys J; Vasconcelos V; Viarengo A;
    Microb Ecol; 2013 May; 65(4):889-900. PubMed ID: 23503989
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.